Contact Us    |      Join    |

"The Voice of Oncology in Massachusetts"

FDA Approved Merck's KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma

June 17, 2024 10:50 AM | Katy Monaco (Administrator)

Merck announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. This approval marks the third endometrial carcinoma indication and the 40th indication overall for KEYTRUDA in the U.S. Read More.


860 Winter Street, Waltham, MA, 02451


tel: 781.434.7329

Massachusetts Society of Clinical Oncologists ©2024

Powered by Wild Apricot Membership Software